Muscular dystrophy gene therapy

Drug Profile

Muscular dystrophy gene therapy

Latest Information Update: 20 Feb 2008

Price : $50

At a glance

  • Originator Medical Research Council; Stanford University School of Medicine; University of Western Australia
  • Class Gene therapies
  • Mechanism of Action Protein stimulants; Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 26 Nov 2003 A preclinical study has been added to the Musculoskeletal disorders pharmacodynamics section
  • 20 Oct 2003 Preclinical trials in Muscular dystrophy in USA (unspecified route)
  • 08 Sep 2003 Preclinical trials in Muscular dystrophy in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top